Rubraca
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
In the current study we investigated the inhibitory effect of rucaparib (Rubraca®) on human ovarian cancer SKOV3 and A2780 cells…
In the present study, the interaction between new drug Rubraca and CNT(4,4-8) nanotube by Density Functional Theory (DFT…
Poly(ADP-ribose) polymerase-1 (PARP-1) is an enzyme involved in signaling and repair of DNA single strand breaks. PARP-1 employs…
BOULDER, Colo.-(BUSINESS WIRE) -June 4, 2018-Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the submission of a regulatory…
Epithelial carcinoma of the ovary is one of the most common gynecologic malignancies.1 The National Cancer Institute estimates…
NEW DRUG APPROVALS Rubraca for Ovarian Cancer The FDA has granted accelerated approval to rucaparib (Rubraca, Clovis Oncology) to…
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA…